Shareholders Have Faith in Loss-making Madrigal Pharmaceuticals (NASDAQ:MDGL) as Stock Climbs 55% in Past Week, Taking Three-year Gain to 267%
Shareholders Have Faith in Loss-making Madrigal Pharmaceuticals (NASDAQ:MDGL) as Stock Climbs 55% in Past Week, Taking Three-year Gain to 267%
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But in contrast you can make much more than 100% if the company does well. For instance the Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) share price is 267% higher than it was three years ago. That sort of return is as solid as granite. In more good news, the share price has risen 62% in thirty days. This could be related to the recent financial results that were recently released - you could check the most recent data by reading our company report.
購買公司股票後最糟糕的結果(假設沒有槓桿)是你投入的資金全部損失。但相反,如果公司表現良好,你可以獲得超過100%的利潤。例如,Madrigal Pharmaceuticals,Inc.(納斯達克:MDGL)的股價比三年前高出267%。這種回報非常穩定。更值得高興的是,股價在三十天內上漲了62%。這可能與最近公佈的財務業績有關-您可以通過閱讀我們的公司報告來查看最新數據。
On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns.
在穩定的七天表現之後,讓我們看看公司的基本面對長期股東回報的影響。
Given that Madrigal Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
鑑於Madrigal Pharmaceuticals在過去十二個月沒有盈利,我們將專注於營業收入增長,以便快速了解其業務發展。當公司沒有盈利時,我們通常希望看到良好的營業收入增長。正如您所想象的,快速的營業收入增長,如果能持續,通常會帶來快速的利潤增長。
In the last 3 years Madrigal Pharmaceuticals saw its revenue grow at 167% per year. That's much better than most loss-making companies. Meanwhile, the share price performance has been pretty solid at 54% compound over three years. This suggests the market has recognized the progress the business has made, at least to a significant degree. Nonetheless, we'd say Madrigal Pharmaceuticals is still worth investigating - successful businesses can often keep growing for long periods.
在過去的3年中,Madrigal Pharmaceuticals的營業收入每年增長了167%。這比大多數虧損公司要好得多。與此同時,股價表現相當堅挺,複合增長率爲3年內的54%。這表明市場已經認識到企業取得的進展,至少在很大程度上如此。儘管如此,我們仍然認爲Madrigal Pharmaceuticals值得調查-成功的企業通常可以持續增長很長時間。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
以下圖像顯示了公司的營業收入和盈利(隨時間變化)(單擊以查看準確的數字)。
Madrigal Pharmaceuticals is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. You can see what analysts are predicting for Madrigal Pharmaceuticals in this interactive graph of future profit estimates.
madrigal pharmaceuticals是一家知名股票,有很多分析師關注,暗示未來增長前景。您可以查看未來利潤預估的交互式圖表,了解分析師對madrigal pharmaceuticals的預測。
A Different Perspective
另一種看法
It's good to see that Madrigal Pharmaceuticals has rewarded shareholders with a total shareholder return of 122% in the last twelve months. That's better than the annualised return of 26% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 3 warning signs for Madrigal Pharmaceuticals that you should be aware of before investing here.
很高興看到madrigal pharmaceuticals在過去十二個月爲股東提供了總股東回報率爲122%。這比過去半個世紀年化回報率26%更好,暗示公司最近表現更好。持樂觀態度的人可能會認爲最近TSR改善表明業務本身正隨着時間變得更好。雖然考慮市場條件對股價的影響非常重要,但有其他更重要的因素。例如,我們發現了3個madrigal pharmaceuticals的警示信號,您在投資之前應該注意這些。
For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.
對於那些喜歡尋找獲勝投資的人來說,最近有內部購買的低估公司免費列表可能是一個很好的選擇。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。
譯文內容由第三人軟體翻譯。